Evaluation of the Tolerance of Three Masks Under Dermatological Control.
2022年3月1日 更新者:Groupe Kolmi Hopen
Monocentric, Open Study for the Evaluation of the Tolerance of Three Class I Medical Devices Under Dermatological Control.
This is a monocentric, open and randomized study.
The purpose is to evaluate the cutaneous tolerance of three medical masks (class I medical device) after 3 consecutive days of use on a population with normal or sensitive skin.
研究概览
研究类型
介入性
注册 (实际的)
98
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
Villeurbanne、法国、69100
- Laboratoire Eurofins Dermscan Pharmascan
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
是的
有资格学习的性别
全部
描述
Inclusion Criteria:
- Healthy Subject;
- Sex: male or female ;
- Age: more than 18 years ;
- Phototype: I to IV on the Fitzpatrick scale;
- For half of the population in each group : subject presenting a sensitive skin on the face confirmed by an interrogatory with the investigator (see Appendix 19.1).
- Subjects who did not use any new cosmetic product on the face in the past 30 days and who agree not to change them during the study period.
- Subject having given freely and expressly his/her informed consent;
- For subjects randomized to group 3: Fit test FFP on M52014-WH
Exclusion Criteria:
In terms of population
- Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship;
- Subject in a social or sanitary establishment;
- Subject suspected to be non-compliant according to the investigator's judgment;
- Subject enrolled in another clinical trial or which exclusion period is not over.
- Subject majors under curatorship, safeguard of justice, activated future protection mandate or family authorization In terms of associated pathology
- Subject with a condition or receiving a medication which, in the investigator's judgment, put the subject at undue risk;
- Subject suffering from a severe or progressive disease.
- Subject's with too many hairs, bears,(to put above) skin lesions, skin disease or severe acne on the face that could interfere with the tolerance evaluation.
- Subject' who is allergic to one or several component of the studied devices. Relating to previous or ongoing treatment
Subject undergoing a topical treatment on the test area or a systemic treatment:
- anti-inflammatory medication and/or antihistamines during the 2 weeks prior to screening and during the study;
- corticosteroids during the 2 weeks and prior to screening and during the study;
- retinoids and/or immunosuppressors during the 3 months prior to screening and during the study;
Subject having started or changed any hormonal treatment during the three previous months.
In terms of lifestyle
- Intensive exposure to sunlight or UV-rays within the previous month and/or foreseen during the study;
- Subject planning to change her/his life habits during the study;
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:其他
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Investigational device#1 = Kolmi® Op-AirTM KALM
|
During 3 consecutive days
|
|
实验性的:Investigational device#2 = Kolmi® Op-Air OneTM
|
During 3 consecutive days
|
|
实验性的:Investigatonal device#3 = Kolmi® Op Air-Pro® Oxygen
|
During 3 consecutive days
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Cutaneous tolerance
大体时间:Days 3
|
Evaluation of the percentage of subjects presenting no relevant clinical or functional signs of cutaneous intolerance after 3 days of use of the three medical devices
|
Days 3
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Subjective appreciation
大体时间:3 days
|
Analysis of the subject's answer to a subjective evaluation questionnaire
|
3 days
|
|
Number of Adverse event
大体时间:3 days
|
Collection of cutaneous and systemic Adverse Event
|
3 days
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Siham Rharbaoui、Eurofins DERMSCAN PHARMASCAN
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2022年1月3日
初级完成 (实际的)
2022年2月17日
研究完成 (实际的)
2022年2月17日
研究注册日期
首次提交
2021年12月22日
首先提交符合 QC 标准的
2022年1月14日
首次发布 (实际的)
2022年1月18日
研究记录更新
最后更新发布 (实际的)
2022年3月2日
上次提交的符合 QC 标准的更新
2022年3月1日
最后验证
2022年3月1日
更多信息
与本研究相关的术语
其他研究编号
- 21E2022
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
未定
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.